Effect of glucagon-like peptide-1 receptor agonists on respiratory drive in patients with obesity and type 2 diabetes: a retrospective case-control study of the SOON cohort
Extract GLP-1 receptor agonists (GLP-1RAs) have been used for around twenty years in the treatment of type 2 diabetes. Extensive research programs have since evaluated the effect of higher doses to repurpose these molecules in the treatment of obesity and its complications. The observed effects on weight loss range from −6% to −20% of total body weight, depending on the molecules studied. Through this weight loss, but also likely via other processes, GLP-1RAs protect renal function, improve metabolic associated steato-hepatitis (MASH), heart failure and knee osteoarthritis, and reduce the risk of cardiovascular events [1].
Authors
- Matthieu Roustit (ORCID: https://orcid.org/0000-0003-4475-1626)
- Sam Bayat (ORCID: https://orcid.org/0000-0002-8565-0293)
- Anne‐Laure Borel (ORCID: https://orcid.org/0000-0002-7368-172X)
- Mathilde Quema
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1183/23120541.01236-2026
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00